KYTX Stock Analysis: Buy, Sell, or Hold?
KYTX - Kyverna Therapeutics, Inc. Common Stock
$8.42
0.29 (3.57%)
▲
5d:
+3.06%
30d:
+15.5%
90d:
-5.39%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When KYTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: KYTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: KYTX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: KYTX is currently trading at $8.42, which is considered extended relative to its 30-day fair value range of $7.26 to $8.35.
Technical Outlook: Technically, KYTX is in a downtrend. Immediate support is located at $7.78, while resistance sits at $9.14. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: KYTX scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.40 (+261.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KYTX is in a downtrend. Immediate support is located at $7.78, while resistance sits at $9.14. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: KYTX scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.40 (+261.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.26 -
$8.35
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 261.0% below Wall St target ($30.40)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.26 -
$8.35
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.78
Resistance Level
$9.14
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.74
Wall Street Target
$30.40
(+261.0%)
Share & Embed Analysis
Last updated: August 24, 2026 7:10 AM ET
Data refreshes hourly during market hours. Next update: 8:10 AM
Data refreshes hourly during market hours. Next update: 8:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
